These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11939847)

  • 21. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effective not only in rheumatism and arthrosis. Rofecoxib fights also acute pain].
    MMW Fortschr Med; 2002 Feb; 144(7):68. PubMed ID: 11887740
    [No Abstract]   [Full Text] [Related]  

  • 23. Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
    Ann Intern Med; 2003 May; 138(10):I39. PubMed ID: 12755582
    [No Abstract]   [Full Text] [Related]  

  • 24. The cyclooxygenase-2-selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence.
    Rahme E; Barkun AN; Toubouti Y; Bardou M
    Gastroenterology; 2003 Aug; 125(2):404-12. PubMed ID: 12891542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclooxygenase-2 enzyme inhibitors: place in therapy.
    Noble SL; King DS; Olutade JI
    Am Fam Physician; 2000 Jun; 61(12):3669-76. PubMed ID: 10892637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F; Michaud K; Burke TA; Zhao SZ
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective.
    Hochberg MC
    Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are rofecoxib and celecoxib safer NSAIDS?
    Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
    Blondon H
    Presse Med; 2000 Mar; 29(9):482-3. PubMed ID: 10745938
    [No Abstract]   [Full Text] [Related]  

  • 30. Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib.
    Brinker A; Nourjah P
    Am J Health Syst Pharm; 2005 Apr; 62(7):739-43. PubMed ID: 15790802
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of cyclooxygenase-2-specific inhibitors.
    Cannon GW; Breedveld FC
    Am J Med; 2001 Feb; 110 Suppl 3A():6S-12S. PubMed ID: 11173044
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating pain after Vioxx. Should you switch to another COX-2, a traditional non-steroidal anti-inflammatory, or acetaminophen.
    Health News; 2005 Jan; 11(1):3-4. PubMed ID: 15726703
    [No Abstract]   [Full Text] [Related]  

  • 33. Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.
    Collantes-Estevez E; Fernandez-Perez C
    Curr Med Res Opin; 2003; 19(5):402-10. PubMed ID: 13678477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery.
    Reuben SS; Connelly NR
    Anesth Analg; 2000 Nov; 91(5):1221-5. PubMed ID: 11049912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The cox-2 inhibitors.
    Strassels S
    J Mass Dent Soc; 1999; 48(3):43-4. PubMed ID: 10808349
    [No Abstract]   [Full Text] [Related]  

  • 36. COX-2 inhibitors still eyed for cancer prevention.
    Thompson CA
    Am J Health Syst Pharm; 2005 May; 62(9):890, 894. PubMed ID: 15851492
    [No Abstract]   [Full Text] [Related]  

  • 37. Pain management in osteoarthritis: a focus on onset of efficacy--a comparison of rofecoxib, celecoxib, acetaminophen, and nabumetone across four clinical trials.
    Battisti WP; Katz NP; Weaver AL; Matsumoto AK; Kivitz AJ; Polis AB; Geba GP
    J Pain; 2004 Nov; 5(9):511-20. PubMed ID: 15556830
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early trials probe COX-2 inhibitors' cancer-fighting potential.
    Ziegler J
    J Natl Cancer Inst; 1999 Jul; 91(14):1186-7. PubMed ID: 10413412
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinical use of COX-2 inhibitors].
    Ristić GG; Stefanović DZ
    Vojnosanit Pregl; 2001; 58(3):283-95. PubMed ID: 11548555
    [No Abstract]   [Full Text] [Related]  

  • 40. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
    Wynn RL
    Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.